Evidence map›Paper›PMID 40751857›Full record

ArticleDiscover oncology2025

Multi-omics and Mendelian randomization study explores potential therapeutic targets for meningiomas.

Yongxue Li, Lihao Lin, Wenhui Zhang, Yan Wang, Haoyu Shen, Yi Guan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yongxue LiDepartment of Neurosurgery, The First Hospital of Jilin University, Changchun, People's Republic of China.
Lihao LinDepartment of Neurosurgery, The First Hospital of Jilin University, Changchun, People's Republic of China.
Wenhui ZhangDepartment of Neurosurgery, The Second Hospital of Tianjin Medical University, Tianjin, China.
Yan WangDepartment of Neurosurgery, The First Hospital of Jilin University, Changchun, People's Republic of China.
Haoyu ShenDepartment of Neurosurgery, The First Hospital of Jilin University, Changchun, People's Republic of China.
Yi GuanDepartment of Neurosurgery, The First Hospital of Jilin University, Changchun, People's Republic of China. guanyi@jlu.edu.cn.

Funding

Natural Science Fund Project of the Jilin Province Science and Technology Department No. YDZJ202501ZYTS046
6 · The paper itself

Abstract

backgroundMeningioma is a common primary central nervous system tumor that can cause a heavy burden on patients. Despite its well-established treatment modalities, pharmacological treatments are not sufficiently abundant. Therefore, we explored potential therapeutic targets for meningiomas by integrating genomic and proteomic data.

methodsWe integrated meningioma data from the UK Biobank and Finnish databases and subsequently explored potential therapeutic targets for meningiomas through multi-omics data using bioinformatics techniques and Mendelian randomization. These targets were finally evaluated using phenotype-wide association group analysis.

resultsWe found that BET1L, COL17A1, CFAP43, SH3PXD2A, TTC28, ZNRF3, SLK, AKR1C3, NRXN3, and RSPO3 can be potential therapeutic targets for meningiomas.

conclusionThis study provides evidence and explores the biological significance of BET1L, COL17A1, CFAP43, SH3PXD2A, TTC28, ZNRF3, SLK, AKR1C3, NRXN3, and RSPO3 as potential therapeutic targets for meningiomas, providing new insights into the development of targeted therapy for meningiomas.

Indexed as

Genome-wide association studyMendelian randomizationMeningiomaTherapeutic target

Identifiers

PMID40751857
PMCPMC12317957

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.